mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development
mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development |
https://doi.org/10.18632/oncotarget.26668
Laura Molina,
Hong Yang,
Adeola O. Adebayo Michael,
Michael Oertel,
Aaron Bell,
Sucha Singh,
Xin Chen,
Junyan Tao,
and Satdarshan P.S. Monga
|
1475-1490 |
The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner
The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner |
https://doi.org/10.18632/oncotarget.26673
Tatsuo Kido,
Yunmin Li,
Yuichiro Tanaka,
Rajvir Dahiya,
and Yun-Fai Chris Lau
|
1491-1506 |
TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma
TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma |
https://doi.org/10.18632/oncotarget.26682
Sandy Tretbar,
Peter Krausbeck,
Anja Müller,
Michael Friedrich,
Christoforos Vaxevanis,
Juergen Bukur,
Simon Jasinski-Bergner,
and Barbara Seliger
|
1507-1524 |
POPX2 is a novel LATS phosphatase that regulates the Hippo pathway
POPX2 is a novel LATS phosphatase that regulates the Hippo pathway |
https://doi.org/10.18632/oncotarget.26689
Muhammad Bakhait Rahmat,
Songjing Zhang,
and Cheng-Gee Koh
|
1525-1538 |
Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy
Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy |
https://doi.org/10.18632/oncotarget.26723
Jian Cui,
Lin Yang,
Lei Guo,
Yongfu Shao,
Dongfeng Tan,
Ni Li,
and Haizeng Zhang
|
1539-1539 |